Prognostic and clinical value of Sirt1 expression in gastric cancer: A systematic meta-analysis
Prognostic and clinical value of Sirt1 expression in gastric cancer: A systematic meta-analysis
复制标题
Sirt1 表达在胃癌中的预后和临床价值：系统荟萃分析
DOI：
10.1007/s11596-016-1580-0
复制
发表时间：
2016-04-01
影响因子：
--
通讯作者：
Shu, Xiao-gang
中科院分区：
文献类型：
--
作者：
Jiang, Bin;Chen, Jin-huang;Shu, Xiao-gang
许多研究报道沉默信息调节因子1（Sirt 1）的表达与胃癌患者的临床特征和预后有关，但其确切功能仍存在争议。本研究旨在阐明Sirt 1在胃癌中的临床和预后价值。检索Pubmed、科克伦图书馆、Embase、中国知网（CNKI）等数据库中2015年12月以前的相关文献。根据纳入标准和排除标准纳入和排除研究。采用RevMan 5.3软件分析3、5年总生存率（OS）及年龄、T分期、N分期、分化程度等临床特征。根据纳入标准和排除标准，7项研究共纳入1650例患者。Sirt 1在58.4%的乳腺癌中呈高表达。Sirt 1高表达与3年OS（OR=0.25，95%CI：0.16- 0.39，P <0.00001，固定）、患者年龄（≥60岁vs. <60岁; OR=1.43，95%CI：1.06- 1.93，P =0.02，固定），T分期（T3+ T4 vs. T1+T2; OR=1.45，95%CI：1.08- 1.94，P =0.01，固定），N期（N1+N2+ N3 vs. N 0; OR=3.47，95%CI：2.39- 5.05，P <0.00001，固定）与肿瘤分化程度（G1+ G2 vs. G3; OR=0.50，95%CI：0.35- 0.69，P <0.0001，固定）。Sirt 1高表达与5年OS无明显相关性（OR=0.44，95%CI：0.15- 1.28，P =0.13，随机）。提示Sirt 1的高表达在较短时间内（3年）提示胃癌患者预后不良，而在较长时间内（≥5年）则提示胃癌患者预后不良。Sirt 1的表达与患者的年龄、T分期、N分期及肿瘤分化程度有关。
Many studies have reported that the expression of silent information regulator 1 (Sirt1) is associated with the clinical features and prognosis of patients with gastric cancer, but the exact function remains controversial. We conducted this study to illustrate the clinical and prognostic value of Sirt1 in gastric cancer. The related publications before December 2015 were searched in the databases including Pubmed, Cochrane Library, Embase and China National Knowledge Infrastructure (CNKI). The studies were included and excluded according to the inclusion criteria and exclusion criteria. The 3- and 5-year overall survival (OS) and clinical features such as age, T stage, N stage and differentiation were analyzed by software RevMan 5.3. A total of 1650 patients in 7 studies were included according to the inclusion criteria and exclusion criteria. The high expression of Sirt1 was found in 58.4% cases by immunohistochemistry. High expression of Sirt1 was closely linked with the 3-year OS (OR=0.25, 95% CI: 0.16–0.39,P<0.00001, fixed), patient’s age (≥60 years oldvs. <60 years old; OR=1.43, 95% CI: 1.06–1.93,P=0.02, fixed), T stage (T3+T4vs. T1+T2; OR=1.45, 95% CI: 1.08–1.94,P=0.01, fixed), N stage (N1+N2+N3vs. N0; OR=3.47, 95% CI: 2.39–5.05,P<0.00001, fixed) and tumor differentiation (G1+G2vs. G3; OR=0.50, 95% CI: 0.35–0.69,P<0.0001, fixed). Nevertheless, it seemed that high expression of Sirt1 was not associated with 5-year OS (OR=0.44, 95% CI: 0.15–1.28,P=0.13, random). It was suggested that the high expression of Sirt1 implies a poor prognosis of gastric cancer patients in a relatively short period (3 years), but not in a long time (≥5 years). The expression of Sirt1 is also linked with patients’ age, T stage, N stage and tumor differentiation.